+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating whether adding sacituzumab tirumotecan to pembrolizumab after surgery improves treatment outcomes for adults with resectable non-small cell lung cancer NSCLC who did not achieve a complete response after initial therapy. The study focuses on comparing disease-free survival between participants receiving pembrolizumab alone and those receiving a combination of pembrolizumab and sacituzumab tirumotecan. The trial is a phase 3, randomized, open-label study sponsored by Merck Sharp & Dohme LLC. Participants first receive pembrolizumab combined with platinum-based doublet chemotherapy as neoadjuvant therapy before surgery. After surgery, participants who did not achieve pathological complete response are assigned to one of two groups one group receives sacituzumab tirumotecan every two weeks for up to 12 doses alongside pembrolizumab every six weeks for up to seven cycles, while the other group receives pembrolizumab monotherapy every six weeks for up to seven cycles. The neoadjuvant chemotherapy includes drugs such as cisplatin, pemetrexed, gemcitabine, carboplatin, and paclitaxel, chosen based on tumor histology. Throughout the study, participants will be monitored regularly with assessments including imaging scans to evaluate disease status and quality of life questionnaires. The primary outcome is disease-free survival assessed by blinded independent central review for up to approximately 93 months. Secondary outcomes include overall survival, lung cancer-specific survival, adverse events, and changes in physical functioning and symptoms related to lung cancer. The study duration can last up to nearly 10 years with follow-up visits to monitor health and treatment effects.

Age: 18Years +All GendersPhase 3
270 locations
C

Actively Recruiting

Researchers are investigating the efficacy and safety of arlo-cel BMS-986393, a GPRC5D-directed CAR-T cell therapy, compared with standard treatment regimens for adults who have relapsed or refractory multiple myeloma and have been previously exposed to lenalidomide. This phase 3, randomized, open-label study aims to assess outcomes in this specific patient group with multiple myeloma. Participants will be assigned to receive either the experimental treatment arlo-cel or one of the standard regimens, which may include drugs such as cyclophosphamide, fludarabine, daratumumab, pomalidomide, dexamethasone, or carfilzomib. Treatments are given at specified doses on scheduled days according to the study protocol. The study is designed with two arms running in parallel to compare these treatment approaches. Throughout the study and for up to five years after the last participant is randomized, researchers will monitor progression-free survival, minimal residual disease status, overall survival, response rates, and quality of life using various established measures. Participants will undergo regular clinical evaluations and assessments to track disease status and treatment effects. Safety and efficacy data will be collected over the long term to better understand the impact of these therapies for multiple myeloma.

Age: 18Years +All GendersPhase 3
141 locations
S

Actively Recruiting

Researchers are evaluating pembrolizumab combined with carboplatin and taxane chemotherapy followed by pembrolizumab with or without maintenance sacituzumab tirumotecan sac-TMT as a first-line treatment for metastatic squamous non-small cell lung cancer NSCLC. This phase 3 study aims to determine if adding maintenance sac-TMT improves overall survival compared to pembrolizumab alone. Participants first undergo an induction phase consisting of four cycles of pembrolizumab every three weeks, carboplatin every three weeks, and either paclitaxel every three weeks or nab-paclitaxel weekly. After induction, participants are randomly assigned to receive either pembrolizumab maintenance alone or pembrolizumab combined with sac-TMT maintenance. The maintenance phase involves pembrolizumab every six weeks for up to 96 weeks and sac-TMT infusions every two weeks until discontinuation criteria are met. Throughout the study, participants will have tumor assessments, scans, and evaluations to monitor disease status, side effects, and quality of life. Researchers will measure overall survival up to approximately 50 months and progression-free survival up to 79 months, along with patient-reported symptoms such as dyspnea, cough, and chest pain. Safety monitoring includes tracking adverse events and treatment discontinuations. The total participation may last several years as long-term outcomes are assessed.

Age: 18Years +All GendersPhase 3
217 locations
S

Actively Recruiting

Researchers are evaluating the combination of sacituzumab tirumotecan and pembrolizumab compared to pembrolizumab alone in treating people with metastatic non-small cell lung cancer NSCLC who have high levels of PD-L1 expression at least 50%. The study aims to see whether adding sacituzumab tirumotecan improves overall survival compared to pembrolizumab alone. This is a phase 3, randomized, open-label trial sponsored by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either sacituzumab tirumotecan plus pembrolizumab or pembrolizumab alone. Sacituzumab tirumotecan is given by intravenous infusion on Days 1, 15, and 29 of each 6-week cycle, while pembrolizumab is administered by intravenous infusion on Day 1 of each 6-week cycle for up to 18 cycles. Supportive medications such as diphenhydramine, an H2 antagonist, acetaminophen, and dexamethasone are given around the first four infusions of sacituzumab tirumotecan to help manage infusion reactions. During the study, participants undergo assessments including overall survival, progression-free survival, response rates, and quality of life measured by validated questionnaires. Safety is monitored throughout the treatment period and beyond. The study tracks symptoms like cough, chest pain, and breathing difficulties, along with adverse events and treatment discontinuations. The total follow-up for outcomes may extend up to approximately 77 months, allowing for long-term monitoring of treatment effects and safety.

Age: 18Years +All GendersPhase 3
220 locations
P

Actively Recruiting

Researchers are evaluating the combination of izalontamab brengitecan Iza-bren with osimertinib compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy for participants with previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer NSCLC. This Phase III randomized study aims to assess these treatments as first-line therapy in this patient population. Participants will receive one of the study treatments Iza-bren combined with osimertinib, osimertinib alone, or osimertinib combined with platinum-based chemotherapy including drugs such as pemetrexed, carboplatin, or cisplatin. Drug doses are specified on certain days, and treatment continues as per protocol. The study design is parallel and open-label with random assignment to one of the treatment arms. During the study, participants will be monitored through assessments including progression-free survival measured by blinded independent central review and investigator evaluation up to approximately three years. Additional evaluations include overall survival, objective response rates, disease control rates, and duration of response measured up to about five years. Safety and treatment effects will be closely observed throughout the study period which may last several years.

Age: 18Years +All GendersPhase 3
204 locations
S

Actively Recruiting

Researchers are evaluating a new combination treatment of Sigvotatug Vedotin plus pembrolizumab compared to pembrolizumab alone in people with non-small cell lung cancer NSCLC that has high levels of PD-L1 protein. This protein can limit the bodys immune response to cancer. The study focuses on participants with advanced NSCLC Stage 3 or 4 who have PD-L1 expression in over 50% of their cancer cells and who are eligible for pembrolizumab treatment. All participants will receive pembrolizumab through an intravenous infusion every six weeks at the study clinic. Half of the participants will also receive Sigvotatug Vedotin as an intravenous infusion every two weeks alongside pembrolizumab. Participants may continue pembrolizumab treatment for up to about two years, while those receiving Sigvotatug Vedotin can continue until their cancer no longer responds to treatment. During the study, participants will visit the clinic regularly for monitoring, including assessments of overall survival and progression-free survival over approximately two years. The research team will evaluate how well participants respond to treatment and monitor side effects. Additional laboratory tests will assess drug levels and immune responses. The total study participation may last up to four years, with ongoing evaluations to measure treatment effects and safety.

Age: 18Years +All GendersPhase 3
389 locations